GFRA2 - GDNF Family Receptor Alpha 2

📖 Wiki Page

gene1435 wordssynced 2026-04-02

GFRA2 - GDNF Family Receptor Alpha 2

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GFRA2 - GDNF Family Receptor Alpha 2</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Ligand</td>
</tr>
<tr>
<td class="label">GFRα1</td>
<td>GDNF</td>
</tr>
<tr>
<td class="label">GFRα2</td>
<td>Neurturin</td>
</tr>
<tr>
<td class="label">GFRα3</td>
<td>Artemin</td>
</tr>
<tr>
<td class="label">GFRα4</td>
<td>GDNF-like (fish)</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Amino Acids</td>
</tr>
<tr>
<td class="label">Signal peptide</td>
<td>1-21</td>
</tr>
<tr>
<td class="label">Propeptide</td>
<td>22-29</td>
</tr>
<tr>
<td class="label">Extracellular domain</td>
<td>30-330</td>
</tr>
<tr>
<td class="label">LFHL domains</td>
<td>60-330</td>
</tr>
<tr>
<td class="label">GPI anchor</td>
<td>C-terminus</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV2-NRTN (CERE-120)</td>
</tr>
<tr>
<td class="label">Protein delivery</td>
<td>Recombinant NRTN</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>RET agonists</td>
</tr>
<tr>
<td class="label">Cell therapy</td>
<td>NRTN-expressing cells</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">GFRA2 expression</td>
<td>Brain tissue</td>
</tr>
<tr>

...

GFRA2 - GDNF Family Receptor Alpha 2

Introduction

GFRA2 (GDNF Family Receptor Alpha 2, also known as GFRα2) is a critical GPI-anchored cell surface receptor that mediates the biological effects of neurturin (NRTN) and other GDNF family ligands. As a key component of the GDNF family signaling system, GFRA2 plays essential roles in the development, survival, and maintenance of dopaminergic neurons, motor neurons, and peripheral neurons.

In the context of neurodegenerative diseases, the GFRA2/neurturin signaling axis has been extensively studied as a therapeutic target for Parkinson's disease, with clinical trials investigating gene therapy approaches to deliver neurotrophic support to degenerating dopaminergic neurons[@bartus2017][@parkinsons2015].

Overview

The GFRA2 receptor is a member of the GDNF receptor alpha (GFRα) family, which includes four related proteins (GFRα1-4) that serve as high-affinity receptors for GDNF family ligands[@gdnfret2001]:

GFRA2 is unique among the GFRα family for its restricted expression pattern and specific role in neuronal survival. It signals primarily through the RET receptor tyrosine kinase to activate pro-survival pathways including PI3K/Akt and MAPK/ERK[@biology2019].

Structure

Protein Architecture

GFRA2 is a approximately 40-45 kDa GPI-anchored protein with distinct structural features:

Mermaid diagram (expand to render)

Domain Organization

Ligand Binding

GFRA2 binds neurturin with high affinity (Kd ~10-20 pM) through its extracellular domain:

Three LFHL (LGF, FSC1, Hesperdin) modules form the ligand-binding interface
The binding site is distinct from GFRα1
Neurturin binding induces GFRA2 dimerization

Post-Translational Modifications

GFRA2 undergoes several modifications:

N-linked glycosylation: Multiple sites in extracellular domain
GPI anchor addition: C-terminal signal for membrane attachment
Proteolytic cleavage: Can release soluble receptor forms

Normal Function

Signaling Mechanisms

GFRA2 mediates neurturin signaling through two primary mechanisms [@paratcha2002][@neurotrophins2003]:

Mermaid diagram (expand to render)

RET-Dependent Signaling

When neurturin binds to GFRA2:

GFRA2 dimerizes and recruits RET

RET autophosphorylates on tyrosine residues

Downstream pathways are activated

PI3K/Akt Pathway:

Activates Akt (PKB)
Promotes cell survival
Inhibits pro-apoptotic proteins
Activates mTORC1

MAPK/ERK Pathway:

Activates Ras/Raf/MEK/ERK cascade
Promotes neuronal differentiation
Regulates gene expression
Supports long-term survival

Biological Functions

In the normal nervous system, GFRA2/neurturin signaling supports [@other1998]:

Dopaminergic Neuron Survival

Promotes survival of substantia nigra pars compacta neurons
Maintains tyrosine hydroxylase expression
Supports dendrite arborization

Motor Neuron Function

Supports facial nucleus motor neurons
Promotes spinal cord motor neuron survival
Maintains neuromuscular junctions

Enteric Nervous System

Essential for enteric neuron development
Supports gut motility
Maintains neuronal populations

Peripheral Neurons

Sympathetic neuron survival
Sensory neuron support
Parasympathetic neuron maintenance

Non-neuronal Functions

Kidney development (minor role)
Testicular function
Cancer cell biology

Role in Neurodegenerative Diseases

Parkinson's Disease

GFRA2/neurturin is one of the most studied neurotrophic systems in PD [@aavmediated2011][@randomized2006]:

Rationale for therapy:

GDNF and neurturin support dopaminergic neuron survival
PD involves progressive loss of substantia nigra neurons
Neurotrophic factors could slow or halt degeneration

Clinical trials:

CERE-120 (AAV2-NRTN): Gene therapy delivering neurturin
Phase I/II trials showed some motor improvements
Phase IIb failed to meet primary endpoint
Post-hoc analysis suggested benefit in younger patients
Direct GDNF infusion: Multiple trials (Amgen, NINDS)
Showed promising results in some patients
Delivery challenges limited efficacy

Current status:

Newer AAV vectors being developed
Combination approaches with other neurotrophic factors
Cell-based delivery systems under investigation

Amyotrophic Lateral Sclerosis

GFRA2 in ALS [@neurotrophic2009]:

Motor neuron support:

Neurturin can protect motor neurons
Supports neuromuscular junction integrity
May delay disease progression

Therapeutic potential:

AAV-NRTN being studied
Combination with other neurotrophic factors
Gene therapy approaches

Other Neurodegenerative Disorders

Peripheral neuropathies:

GFRA2 supports sensory neurons
Being explored for diabetic neuropathy
Charcot-Marie-Tooth disease research

Enteric neurodegeneration:

Hirschsprung disease association
Gut motility disorders

Therapeutic Targeting

Neurotrophic Factor Therapy

Challenges

Key challenges in targeting GFRA2 for neurodegeneration [@tdwells2019]:

Delivery: Getting neurotrophic factors to the brain

Blood-brain barrier: Limited CNS penetration

Dosing: Optimal dose unclear

Patient selection: Biomarkers needed

Timing: When to treat in disease course

Safety: Potential off-target effects

Future Directions

New viral vectors with improved tropism
Targeted delivery to specific brain regions
Combination with neuroprotective drugs
Biomarker development for patient selection

Biomarkers

Clinical Correlations

GFRA2 biomarkers may indicate:

Patient suitability for neurotrophic therapy
Treatment response
Disease progression

Cross-Pathway Interactions

GFRA2 intersects with multiple neurodegenerative pathways [@gdnfret2015]:

Mermaid diagram (expand to render)

Mitochondrial function: Pro-survival signaling
Autophagy: Regulation of protein clearance
Synaptic plasticity: Support of synaptic connections
Neuroinflammation: Modulation of glial responses

Background

The study of Gfra2 Gdnf Family Receptor Alpha 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[GFRA2 Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/2675)
[UniProt O00509 - GFRA2](https://www.uniprot.org/uniprot/O00509)
[GDNF Family - R&D Systems](https://www.rndsystems.com/categories/gdnf-family)

References

[- Airaksinen MS, Saarma M, "The GDNF family: signalling, biological functions and therapeutic value." Nature Reviews Neuroscience (2002)](https://pubmed.ncbi.nlm.nih.gov/11988777/)

[- Baloh RH, Enomoto H, Johnson EM Jr, Milbrandt J, "The GDNF family ligands and receptors." Current Opinion in Neurobiology (2000)](https://pubmed.ncbi.nlm.nih.gov/10679430/)

[Unknown, - Bartus RT, Johnson EM Jr. "Clinical tests of neurotrophic factors for human neurodegenerative diseases." Neurobiology of Disease. 2017;97:97-109 (2017)](https://pubmed.ncbi.nlm.nih.gov/27452340/)

[- Kalia LV, Lang AE, "Parkinson's disease." Lancet (2015)](https://pubmed.ncbi.nlm.nih.gov/25904081/)

[- Takahashi M, "The GDNF/RET signaling pathway and human diseases." Cytokine & Growth Factor Reviews (2001)](https://pubmed.ncbi.nlm.nih.gov/11714563/)

[- Ibáñez CF, Andressoo JO, "Biology of GDNF and its receptors - relevance to disorders of the central nervous system." Handbook of Experimental Pharmacology (2019)](https://pubmed.ncbi.nlm.nih.gov/30809752/)

[Unknown, - Paratcha G, Ibáñez CF. "GDNF and GFRα: a versatile neuronal unit signaling machine." Nature Reviews Neuroscience. 2002;3(5):382-394 (2002)](https://pubmed.ncbi.nlm.nih.gov/11988776/)

[- Chao MV, "Neurotrophins and their receptors: a convergence point for many signalling pathways." Nature Reviews Neuroscience (2003)](https://pubmed.ncbi.nlm.nih.gov/12671746/)

- Saarma M, Sariola H, "Other neurotrophic factors: GDNF and NTN." Mental Retardation and Developmental Disabilities Research Reviews (1998)

[- Bartus RT, Brown L, Pérez A, et al, "AAV2-mediated gene therapy for neurotrophic factor delivery." Molecular Therapy (2011)](https://pubmed.ncbi.nlm.nih.gov/21427708/)

[- Lang AE, Gill S, Patel NK, et al, "Randomized controlled trial of intraputaminal GDNF infusion." Annals of Neurology (2006)](https://pubmed.ncbi.nlm.nih.gov/16491659/)

[- Sakowski SA, Levenstuen BA, Kim E, et al, "Neurotrophic factors and ALS." Experimental Neurology (2009)](https://pubmed.ncbi.nlm.nih.gov/19703545/)

[-邮箱:TDwells J, Barker RA, "Clinical trials of neurotrophic factors for Parkinson's disease." Movement Disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/30957323/)

[- Kramer ER, Liss B, "GDNF/RET signaling in Parkinson's disease." Journal of Neural Transmission (2015)](https://pubmed.ncbi.nlm.nih.gov/25740052/)

📖 View canonical wiki page →

GFRA2 - GDNF Family Receptor Alpha 2

GFRA2 - GDNF Family Receptor Alpha 2

Introduction

GFRA2 - GDNF Family Receptor Alpha 2

Introduction

Overview

Structure

Protein Architecture

Domain Organization

Ligand Binding

Post-Translational Modifications

Normal Function

Signaling Mechanisms

RET-Dependent Signaling

Biological Functions

Role in Neurodegenerative Diseases

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Other Neurodegenerative Disorders

Therapeutic Targeting

Neurotrophic Factor Therapy

Challenges

Future Directions

Biomarkers

GFRA2-Related Biomarkers

Clinical Correlations

Cross-Pathway Interactions

Background

See Also

External Links

References